Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $7.6 million.

  • Applied Therapeutics' Gains from Investment Securities fell 8103.24% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 9484.4%. This contributed to the annual value of $6.5 million for FY2024, which is 3757.51% up from last year.
  • Per Applied Therapeutics' latest filing, its Gains from Investment Securities stood at $7.6 million for Q3 2025, which was down 8103.24% from $7.7 million recorded in Q2 2025.
  • Applied Therapeutics' 5-year Gains from Investment Securities high stood at $63.4 million for Q1 2024, and its period low was -$76.1 million during Q4 2024.
  • Its 3-year average for Gains from Investment Securities is $9.3 million, with a median of $7.6 million in 2025.
  • Data for Applied Therapeutics' Gains from Investment Securities shows a peak YoY increase of 1361918.98% (in 2024) and a maximum YoY decrease of 54843.18% (in 2024) over the last 5 years.
  • Applied Therapeutics' Gains from Investment Securities (Quarter) stood at $17.0 million in 2023, then plummeted by 548.43% to -$76.1 million in 2024, then soared by 110.02% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q3 2025, $7.7 million for Q2 2025, and $7.1 million during Q1 2025.